Sign In
Buy NUTX
Nutex Health Earnings Calls
| Release date | Apr 30, 2026 |
| EPS estimate | $3.99 |
| EPS actual | $6.52 |
| EPS Surprise | 63.41% |
| Revenue estimate | 227.801M |
| Revenue actual | 216.485M |
| Revenue Surprise | -4.97% |
| Release date | Mar 05, 2026 |
| EPS estimate | $5.56 |
| EPS actual | $1.61 |
| EPS Surprise | -71.04% |
| Revenue estimate | 258.816M |
| Revenue actual | 151.7M |
| Revenue Surprise | -41.39% |
| Release date | Nov 19, 2025 |
| EPS estimate | $1.81 |
| EPS actual | $7.76 |
| EPS Surprise | 328.73% |
| Revenue estimate | 213.812M |
| Revenue actual | 267.804M |
| Revenue Surprise | 25.25% |
| Release date | Oct 22, 2025 |
| EPS estimate | -$1.43 |
| EPS actual | -$2.95 |
| EPS Surprise | -105.81% |
| Revenue estimate | 244M |
| Revenue actual | 243.985M |
| Revenue Surprise | -0.0061% |
Last 4 Quarters for Nutex Health
Below you can see how NUTX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Oct 22, 2025 |
| Price on release | $114.31 |
| EPS estimate | -$1.43 |
| EPS actual | -$2.95 |
| EPS surprise | -105.81% |
| Date | Price |
|---|---|
| Oct 16, 2025 | $96.70 |
| Oct 17, 2025 | $94.84 |
| Oct 20, 2025 | $111.00 |
| Oct 21, 2025 | $114.50 |
| Oct 22, 2025 | $114.31 |
| Oct 23, 2025 | $117.30 |
| Oct 24, 2025 | $125.57 |
| Oct 27, 2025 | $129.48 |
| Oct 28, 2025 | $128.68 |
| 4 days before | 18.21% |
| 4 days after | 12.57% |
| On release day | 2.62% |
| Change in period | 33.07% |
| Release date | Nov 19, 2025 |
| Price on release | $112.19 |
| EPS estimate | $1.81 |
| EPS actual | $7.76 |
| EPS surprise | 328.73% |
| Date | Price |
|---|---|
| Nov 13, 2025 | $108.81 |
| Nov 14, 2025 | $107.11 |
| Nov 17, 2025 | $103.95 |
| Nov 18, 2025 | $99.20 |
| Nov 19, 2025 | $112.19 |
| Nov 20, 2025 | $142.34 |
| Nov 21, 2025 | $136.92 |
| Nov 24, 2025 | $137.21 |
| Nov 25, 2025 | $119.21 |
| 4 days before | 3.11% |
| 4 days after | 6.26% |
| On release day | 26.87% |
| Change in period | 9.56% |
| Release date | Mar 05, 2026 |
| Price on release | $105.34 |
| EPS estimate | $5.56 |
| EPS actual | $1.61 |
| EPS surprise | -71.04% |
| Date | Price |
|---|---|
| Feb 27, 2026 | $110.46 |
| Mar 02, 2026 | $117.60 |
| Mar 03, 2026 | $111.90 |
| Mar 04, 2026 | $108.44 |
| Mar 05, 2026 | $105.34 |
| Mar 06, 2026 | $90.28 |
| Mar 09, 2026 | $98.61 |
| Mar 10, 2026 | $96.78 |
| Mar 11, 2026 | $90.49 |
| 4 days before | -4.64% |
| 4 days after | -14.10% |
| On release day | -14.30% |
| Change in period | -18.08% |
| Release date | Apr 30, 2026 |
| Price on release | $119.20 |
| EPS estimate | $3.99 |
| EPS actual | $6.52 |
| EPS surprise | 63.41% |
| Date | Price |
|---|---|
| Apr 24, 2026 | $108.24 |
| Apr 27, 2026 | $110.79 |
| Apr 28, 2026 | $115.09 |
| Apr 29, 2026 | $112.02 |
| Apr 30, 2026 | $119.20 |
| May 01, 2026 | $139.57 |
| May 04, 2026 | $147.17 |
| May 05, 2026 | $121.00 |
| May 06, 2026 | $130.59 |
| 4 days before | 10.13% |
| 4 days after | 9.56% |
| On release day | 17.09% |
| Change in period | 20.65% |
Nutex Health Earnings Call Transcript Summary of Q1 2026
Nutex Health reported Q1 2026 revenue of $216.5M (up 2% YoY) and net income of $46.8M (vs. $21.2M in Q1 2025). Adjusted EBITDA declined 21% to $57.6M, driven largely by timing/recognition differences related to independent dispute resolution (IDR) arbitration costs. Hospital visits increased 3.1% to ~49.7k (same-hospital growth 0.6%), and population health revenue rose ~14% to $8.9M. Cash on hand improved to $207.3M and net long-term debt declined to $24.3M; operating cash flow was strong at $75.5M. Management completed a $25M share repurchase program and launched a second $25M buyback. Strategically, Nutex will begin directly investing in de novo hospital development (with planned monetization via sale-leasebacks to REITs) to secure a more capital-efficient pipeline, while also investing in AI/IT, staffing, and expanding IPA/population-health capabilities. Management continues to pursue selective in-network payer contracts but relies materially on the IDR arbitration process (submitting ~50–60% of claims, prevailing >85% with collection >80%). The company remains on track to open three additional hospitals in 2026 (San Antonio, Jacksonville, West Little Rock) and expects steady expansion thereafter.
